Author

M. Grobben

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Assay:flow cytometry· 1 Organism:human· 1 Organism:non-human primate· 1 Assay:proteomics· 1

Frequent Co-Authors

G. Kerster· 2 shared I. Bontjer· 2 shared J. A. Burger· 2 shared K. Sliepen· 2 shared K. van der Straten· 2 shared M. Brinkkemper· 2 shared M. Claireaux· 2 shared M. de Gast· 2 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

G. Kerster

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A public antibody class recognizes a novel S2 epitope exposed on open conformations of SARS-CoV-2 spike

M. Claireaux, T. G. Caniels, M. de Gast, J. Han, D. Guerra, G. Kerster, B. D. van Schaik, A. Jongejan, A. I. Schriek, M. Grobben, P. J. Brouwer, K. van der Straten, Y. Aldon, J. Capella-Pujol, J. L. Snitselaar, , M. J. van Gils

The paper identifies a novel S2 epitope recognized by a public antibody class in SARS-CoV-2-reactive B cells, which becomes exposed on vaccine-optimized spike proteins.

bioRxiv · Dec 1, 2021Immunology

Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection

P. J. M. Brouwer, M. Brinkkemper, P. Maisonnasse, N. Dereuddre-Bosquet, M. Grobben, M. Claireaux, M. de Gast, R. Marlin, V. Chesnais, S. Diry, J. D. Allen, Y. Watanabe, J. M. Griezen, G. Kerster, H. L. Turner, , de Bree

This paper develops a two-component spike nanoparticle vaccine that protects macaques from SARS-CoV-2 infection by inducing strong neutralizing antibodies and reducing viral replication.

bioRxiv · Nov 7, 2020Immunology